Published in J Transl Med on February 06, 2015
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Infectious mononucleosis. N Engl J Med (2010) 3.10
Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene (1989) 3.00
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J (1984) 2.77
Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A (1980) 2.59
Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis (2012) 2.33
Biopharmaceutical benchmarks 2006. Nat Biotechnol (2006) 2.10
Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines (2007) 1.79
A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation (2009) 1.77
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis (2008) 1.63
Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J Virol (1988) 1.61
Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med (2011) 1.54
Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol (2006) 1.40
Replication-defective viruses as vaccines and vaccine vectors. Virology (2006) 1.34
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol (2009) 1.28
Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine (2007) 1.20
Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol (2010) 1.14
Epstein-Barr virus--is it time to develop a vaccine program? J Natl Cancer Inst (1976) 1.10
Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol (2010) 1.10
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol (2014) 1.08
Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch Virol (1999) 1.06
Evidence for mixed membrane topology of the newcastle disease virus fusion protein. J Virol (2003) 1.02
Structure and assembly of a paramyxovirus matrix protein. Proc Natl Acad Sci U S A (2012) 1.01
Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep (2013) 0.99
Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood (2008) 0.94
Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant (2005) 0.93
A virus-like particle-based Epstein-Barr virus vaccine. J Virol (2011) 0.92
Self-assembly of Epstein-Barr virus capsids. J Virol (2009) 0.92
Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92
Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol (2000) 0.89
Quantitative detection of viral gene expression in populations of Epstein-Barr virus-infected cells in vivo. Methods Mol Biol (2005) 0.85
Virus-like particles induce robust human T-helper cell responses. Eur J Immunol (2011) 0.85
Animal models of Epstein Barr virus infection. J Immunol Methods (2014) 0.85
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res (2014) 0.84
Three-dimensional structure of the Epstein-Barr virus capsid. J Gen Virol (2012) 0.83
Polyvalent recombinant antigens: a new vaccine strategy. Vaccine (1988) 0.83
Characterization of an alternate form of Newcastle disease virus fusion protein. J Virol (2005) 0.82
An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA. J Virol (2012) 0.82
Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. BMC Biotechnol (2006) 0.81
Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins. Curr Protoc Microbiol (2013) 0.80
A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine (2013) 0.79
Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. Open Virol J (2012) 0.78
Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity. Bioanalysis (2012) 0.76